1. HBW Insight
  2. >>Health
  3. >>Rx-to-OTC Switch

Label Comprehension Results Point Petros Toward OTC Self-Selection Study For Stendra ED Drug

 
• By Malcolm Spicer

Petros considers switch NDA for Stendra (avanafil), approved for Rx sales in US since 2012 on an NDA by Metuchen. Early indicators showed positive outcomes in a 453-subject label comprehension study for the oral PDE5 inhibitor.

• Source: Alamy

Petros Pharmaceuticals Inc. marks the first anniversary of its launch through the merger of Neurotrope Inc. and Metuchen Pharmaceuticals LLC with a report of strong OTC label comprehension results for an erectile dysfunction drug.

Petros is considering submitting a new drug application to the US Food and Drug Administration for an OTC switch of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rx-to-OTC Switch

German Switch Committee Supports OTC Melatonin And Acyclovir, Rejects Rupatadine

 
• By David Ridley

Germany’s Expert Committee for Prescription supports the Rx-to-OTC switches of melatonin and buccal acyclovir but rejects rupatadine.

Navamedic To Market OTC Naloxone In Norway Following Switch

 
• By Tom Gallen

Navamedic adds Ventizolve to its portfolio shortly after Norway switched the opioid overdose reversal drug from Rx to OTC.

Viatris Switches Innovative Dual Action Nasal Spray In The UK

 
• By David Ridley

Now available without a prescription, Dymista Control is the first OTC combination treatment for consumers who are struggling to control their seasonal allergic rhinitis with a corticosteroid or antihistamine nasal spray, according to the firm.

Haleon Study: Self-Care Policies Could Save Finland €60m Per Year

 
• By David Ridley

Creating a working group to drive Rx-to-OTC switch is one of the ways in which Finland could expand self-care and save €60m per year for the country's health system, suggests a recently published report commissioned by Haleon.

More from Health

Futura Launches Eroxon Strategic Review

 
• By Tom Gallen

Weaker than expected sales of OTC ED treatment Eroxon has led Futura to launch a review of the brand's future direction.

Reducing ‘Complexity Across The Organization’ Tops Kenvue Interim CEO’s Priorities

 
• By Malcolm Spicer

Three weeks into his appointment as interim CEO, Kirk Perry sets priorities including “reduce organizational complexity,” “reinforce a consumer-centric mindset” and “refocus on household penetration.”

Softness In US And China Holds Back Bayer Consumer Health

 
• By Tom Gallen

Like its peers, Bayer Consumer Health has struggled in the challenging US market in the first half of 2025 and says it doesn't expect conditions to change this year.